Revascular Therapeutics
Stage
Series B - III | AliveTotal Raised
$7.26MLast Raised
$1M | 13 yrs agoAbout Revascular Therapeutics
ReVascular Therapeutics has pioneered advances in technology for the intravascular treatment of complex lesions and total occlusions that typically cannot be treated using current catheter-based technologies and products.
Missing: Revascular Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Revascular Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Revascular Therapeutics Patents
Revascular Therapeutics has filed 12 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
1/10/2014 | 11/21/2017 | Automotive transmission technologies, Engine technology, Drilling technology, Electric power conversion, Mechanisms (engineering) | Grant |
Application Date | 1/10/2014 |
|---|---|
Grant Date | 11/21/2017 |
Title | |
Related Topics | Automotive transmission technologies, Engine technology, Drilling technology, Electric power conversion, Mechanisms (engineering) |
Status | Grant |
Latest Revascular Therapeutics News
Aug 22, 2013
Launched by Revascular Therapeutics Founder Brian Gormley Join Now Sign In Members Only This is the kind of news coverage and analysis you can access exclusively as a WSJ Pro Member. Copyright 2016 Dow Jones & Company, Inc. All Rights Reserved This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.
Revascular Therapeutics Frequently Asked Questions (FAQ)
Where is Revascular Therapeutics's headquarters?
Revascular Therapeutics's headquarters is located at 766 Palomar Ave, Sunnyvale.
What is Revascular Therapeutics's latest funding round?
Revascular Therapeutics's latest funding round is Series B - III.
How much did Revascular Therapeutics raise?
Revascular Therapeutics raised a total of $7.26M.
Who are the investors of Revascular Therapeutics?
Investors of Revascular Therapeutics include Adams Street Partners, Latterell Venture Partners, BioStar Capital, Charter Life Sciences and Charter Venture Capital.
Who are Revascular Therapeutics's competitors?
Competitors of Revascular Therapeutics include NeoChord, ALung Technologies, Mobius Therapeutics, Vapotherm, Pathfinder Therapeutics and 13 more.
Compare Revascular Therapeutics to Competitors
Zeopane Microneedles is a Hong Kong based company that designs and markets Zeolite micro-needles and insulin delivery patches for diabetes patients.
Cagenix develops and researches new devices for dental implants. The company's main focus is on providing superstructures for multiple dental implants that is used to restore chewing function and aesthetics for patients.
Cardiogenesis is a medical device company committed to innovating tools for the treatment of cardiovascular disease. The company, located in Orange County, California, is a provider in laser revascularization and angiogenic therapies for the treatment of severe angina.
Zeno Corporation is a Houston-based medical technology company engaged in the development of products using its patented ClearPoint technologyˆ as well as other products related to skin care.
CeQur is developing and commercializing advanced yet simple-to-use insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease. The Company's fully optimized device, PaQ, is a three-day, wearable device that provides freedom from multiple daily insulin injections.
Light Sciences Oncology (LSO) is developing Talaporfin Sodium for solid tumors as well as other indications such as BPH. Talaporfin Sodium is a water-soluble drug targeted by a small, single-use, disposable drug activator included with the drug. Talaporfin Sodium is designed to provide tolerable, effective, and repeatable treatments for patients. LSO has completed treatment of patients in a Phase 3 trial of Talaporfin Soduim in hepatocellular carcinoma (HCC), a Phase 3 trial for metastatic colorectal cancer (MCRC) and in Phase 1 and Phase 2 clinical trials in benign prostatic hyperplasia (BPH), or enlargement of the prostate.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.